HLA-B27 did not protect against COVID-19 in patients with axial spondyloarthritis – data from the ReumaCov-Brasil Registry

Table 3 Outcomes related to COVID-19 (only case group), according to the HLA-B27 status in spondyloarthritis patients

Outcomes	HLA-B27 negative (n = 21)		HLA-B27 positive (n = 64)		OR (CI 95%)	P value
Outcomes	n	%	n	%	OR (CI 95%)	P value
Hospital care	5	29.4	12	76.5	0.73 (0.22–2.41)	0.754^*
Hospitalization	4	66.7	2	33.3	0.13 (0.02–0.81)	0.031^**
Intensive unit care	2	50.0	2	50.0	0.30 (0.04–2.32)	0.254^**
Mechanical ventilation	2	66.7	1	33.3	0.50 (0.02–8.95)	1.000^**
Lenght of hospitalization (mean, SD)	5.7 (4.11)		13.5 (14.8)		-1,07 (-2,97-0.96)^ξ	0.594^#
Severity of COVID − 19^δ
Mild	12	20.0	48	80.0	0.44 (0.15–1.24)	0.119^*
Moderate	4	66.7	2	33.3	0.13 (0.02–0.81)	0.031^**
Severe	2	50.0	2	50.0	0.30 (0.04–2.32	0.254^**
Death	1	100	0	0	-	1.000^**

^δMild activity was considered for patients who did not require hospital care, moderate for those who were hospitalized and severe for those who were admitted to the intensive care unit. *Chi-square test (95%CI); **Fisher exact test (95%CI); #t test for independent samples (95%CI); ^ξCohen’s d test for comparing effect size between means (CI 95%)

ISSN: 2523-3106